[go: up one dir, main page]

MX2022010794A - Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1). - Google Patents

Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).

Info

Publication number
MX2022010794A
MX2022010794A MX2022010794A MX2022010794A MX2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A
Authority
MX
Mexico
Prior art keywords
taar1
agonist
salts
crystalline forms
associated receptor
Prior art date
Application number
MX2022010794A
Other languages
English (en)
Inventor
Frank Stowasser
Urs Schwitter
Trussardi, (Fallecido) René
Kirsten Andrea Graeser
Florence Nicole Antoinette Tixeront
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022010794A publication Critical patent/MX2022010794A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas cristalinas y amorfas de sales farmacéuticamente aceptables del agonista de TAAR1 5-etil-4-metil-N-[4-[(2S) morfolin-2-il]fenil]-1H-pirazol-3-carbox amida. También se describen composiciones farmacéuticas adecuadas para la administración a un mamífero que incluyen el agonista de TAAR1, y métodos para el uso del agonista de TAAR1, solo y en combinación con otros compuestos, para tratar enfermedades o afecciones asociadas con la actividad de TAAR1.
MX2022010794A 2020-03-19 2021-03-17 Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1). MX2022010794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
PCT/EP2021/056749 WO2021185878A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Publications (1)

Publication Number Publication Date
MX2022010794A true MX2022010794A (es) 2022-09-27

Family

ID=69846246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010794A MX2022010794A (es) 2020-03-19 2021-03-17 Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).

Country Status (13)

Country Link
US (1) US20230120311A1 (es)
EP (1) EP4121428B1 (es)
JP (2) JP2023517729A (es)
KR (1) KR20220155575A (es)
CN (1) CN115279752A (es)
AU (1) AU2021238632A1 (es)
BR (1) BR112022016746A2 (es)
CA (1) CA3166331A1 (es)
ES (1) ES3044409T3 (es)
IL (1) IL294301A (es)
MX (1) MX2022010794A (es)
TW (1) TWI874616B (es)
WO (1) WO2021185878A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250044870A (ko) * 2022-08-12 2025-04-01 에프. 호프만-라 로슈 아게 5-에틸-4-메틸-n-[4-[(2s) 모르폴린-2-일]페닐]-1h-피라졸-3-카르복스아미드를 포함하는 약제학적 조성물
TW202444712A (zh) * 2023-04-28 2024-11-16 大陸商江蘇豪森藥業集團有限公司 一種嗎啉雜環類化合物的鹽及其製備方法和應用
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
BR112018015389B1 (pt) 2016-03-17 2023-12-19 F. Hoffmann-La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso

Also Published As

Publication number Publication date
TW202140466A (zh) 2021-11-01
CA3166331A1 (en) 2021-09-23
US20230120311A1 (en) 2023-04-20
BR112022016746A2 (pt) 2022-10-11
EP4121428A1 (en) 2023-01-25
AU2021238632A1 (en) 2022-07-14
EP4121428B1 (en) 2025-08-13
CN115279752A (zh) 2022-11-01
TWI874616B (zh) 2025-03-01
JP2023517729A (ja) 2023-04-26
KR20220155575A (ko) 2022-11-23
ES3044409T3 (en) 2025-11-26
JP2025166092A (ja) 2025-11-05
IL294301A (en) 2022-08-01
WO2021185878A1 (en) 2021-09-23
EP4121428C0 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
MX2022010794A (es) Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).
AR066420A1 (es) Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso.
CL2024000552A1 (es) Inhibidores de nlrp3
UY39565A (es) Inhibidores de prmt5 novedosos
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
UY38602A (es) Compuestos tricíclicos condensados
CO2021014292A2 (es) Moduladores de la vía de respuesta integrada al estrés
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CO2022015927A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
PE20081650A1 (es) Combinaciones que comprenden formoterol y salmeterol y sales de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo[2,2,2]octano
PE20121084A1 (es) Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2
AR127050A1 (es) Compuestos espirocíclicos
MX2021015853A (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida.
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
BR112018015389A2 (pt) derivado de 5-etil-4-metil-pirazol-3-carboxamida tendo atividade como agonista de taar
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
MX2022004882A (es) Composicion farmaceutica que comprende selexipag.
DOP2024000209A (es) Compuestos de heteroarilo para el tratamiento del dolor
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2022001820A (es) Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5).
CL2025001713A1 (es) Sal maleato de un antagonista del receptor de melanocortina subtipo 2 cristalino (mc2r).
CL2022001323A1 (es) Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
MX2021012392A (es) Compuestos, composiciones y metodos.